您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MMAD
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MMAD
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MMAD图片
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
MMAD 是一种有效的微管蛋白抑制剂,是抗体药物偶联物 (ADC) 中的一种毒素有效载荷。

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Applications

MMAD is a highly potent inhibitor of tubulin [1]. MMAD is one of the auristatins, which are used as the drugs of antibody drug conjugates (ADCs). In ADCs, the therapeutic compounds and the high selectivity of antibodies are combined by the linkers. By taking advantage of antigen-selectivity of MAbs, it can deliver these cytotoxic drugs to antigen-expressing tumor cells, thus increasing both the efficacy and safety of therapy. As a payload of ADCs, MMAD is used to target the tubulin of the tumor cells. It can interfere with tubulin polymerization and induce rapid cell death at low picomolar concentrations [1]. Additionally, MMAD is reported to be used in the production of site-specific antibody drug conjugates (NDCs). In the NDCs, MMAD is combined with anti-5T4 antibody or anti-Her2 antibody. It is shown that the NDCs demonstrate better efficacy and pharmacokinetics [2].

产品描述

MMAD is a highly potent inhibitor of tubulin [1].

MMAD is one of the auristatins, which are used as the drugs of antibody drug conjugates (ADCs). In ADCs, the therapeutic compounds and the high selectivity of antibodies are combined by the linkers. By taking advantage of antigen-selectivity of MAbs, it can deliver these cytotoxic drugs to antigen-expressing tumor cells, thus increasing both the efficacy and safety of therapy. As a payload of ADCs, MMAD is used to target the tubulin of the tumor cells. It can interfere with tubulin polymerization and induce rapid cell death at low picomolar concentrations [1].

Additionally, MMAD is reported to be used in the production of site-specific antibody drug conjugates (NDCs). In the NDCs, MMAD is combined with anti-5T4 antibody or anti-Her2 antibody. It is shown that the NDCs demonstrate better efficacy and pharmacokinetics [2].

References:
[1] Puja Sapra, Andrea T Hooper, Christopher J, O’Donnell & Hans-Peter Gerber. Investigational antibody drug conjugates for solid tumors. Expert Opin. Investig. Drugs. 2011, 20(8):1131-1149.
[2] Feng Tiana, Yingchun Lu, Anthony Manibusan, Aaron Sellers et al. A general approach to site-specific antibody drug conjugates. PNAS. 2014, February, 111(5): 1766-1771.